Hyalgan

Hyalgan is a prescription intra‑articular injection that contains sodium hyaluronate as its active ingredient. It is supplied as a sterile solution for injection, intended for use in the European market. The product is classified as a viscosupplement and is used to manage symptoms of knee osteoarthritis by supplementing the joint’s natural hyaluronic acid. Hyalgan is administered directly into the joint space under medical supervision by a qualified clinician.

Hyalgan is indicated for the symptomatic treatment of osteoarthritis of the knee, where it is used as a viscosupplement to improve joint function.

- Reduces knee pain associated with osteoarthritis. - Improves joint mobility and range of motion. - Delays the need for surgical interventions such as total knee replacement. - Can be used in patients who have not responded adequately to oral analgesics or NSAIDs. - May be considered as part of a multimodal osteoarthritis management plan. - Administered as a series of weekly injections, typically three to five doses. - Provides a temporary restoration of the viscoelastic properties of synovial fluid.

Adverse reactions to intra‑articular Hyalgan are generally related to the injection procedure and the product itself, and they are usually mild and self‑limiting.

Common: - Mild pain or tenderness at the injection site. - Temporary swelling or effusion of the knee. - Warmth or redness around the joint. - Limited range of motion for a short period after injection. - Transient bruising at the injection site. - Mild headache occasionally following the procedure.

Serious: - Acute joint infection (septic arthritis). - Allergic reaction presenting as rash, itching, or urticaria. - Persistent severe inflammation requiring medical intervention. - Joint effusion with severe pain indicating possible inflammatory reaction.

Before using Hyalgan, clinicians should evaluate patient history and joint condition to minimize risks and ensure appropriate use.

- Confirm diagnosis of knee osteoarthritis and rule out inflammatory arthritis. - Assess for active joint infection or skin infection at the injection site. - Evaluate hypersensitivity to hyaluronic acid preparations or any component of the formulation. - Use caution in patients with severe knee deformities or limited joint space. - Consider alternative therapies for patients with bleeding disorders or on anticoagulant therapy. - Avoid use in pregnant or nursing women due to insufficient safety data.

Hyalgan may interact with other agents administered systemically or locally, and certain combinations require special attention.

Avoid: - Concurrent intra‑articular corticosteroid injections within a short interval, which can diminish the efficacy of hyaluronic acid. - Simultaneous use of intra‑articular antibiotics or other viscosupplements that may increase the risk of joint irritation.

Use with caution: - Systemic anticoagulants or antiplatelet agents, because they may increase bleeding risk at the injection site. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) taken around the time of injection, as they may affect local inflammation response. - Disease‑modifying osteoarthritis drugs (DMOADs) or other intra‑articular therapies, requiring coordinated scheduling. - Patients receiving disease‑modifying biologics, where immune modulation could alter reaction to the injection.